Gentamicin

Gentamicin

Clinical data
Pregnancy category	D
Routes of administration	IV/IM
ATC code	D06AX07 (WHO) J01GB03 (WHO), S01AA11 (WHO), S02AA14 (WHO), S03AA06 (WHO)
Pharmacokinetic data
Bioavailability	limited oral bioavailability
Protein binding	0-10%
Elimination half-life	2 hrs
Excretion	renal
Identifiers
IUPAC name 2-[4,6-diamino-3- [3-amino-6-(1-methylaminoethyl) tetrahydropyran-2-yl] oxy-2-hydroxy- cyclohexoxy]-5-methyl- 4-methylamino-tetrahydropyran-3,5-diol
CAS Number	1403-66-3
PubChem CID	3467
DrugBank	APRD00214
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H43N5O7
Molar mass	477.596 g/mol

WikiDoc Resources for Gentamicin
Articles
Most recent articles on Gentamicin Most cited articles on Gentamicin Review articles on Gentamicin Articles on Gentamicin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Gentamicin Images of Gentamicin Photos of Gentamicin Podcasts & MP3s on Gentamicin Videos on Gentamicin
Evidence Based Medicine
Cochrane Collaboration on Gentamicin Bandolier on Gentamicin TRIP on Gentamicin
Clinical Trials
Ongoing Trials on Gentamicin at Clinical Trials.gov Trial results on Gentamicin Clinical Trials on Gentamicin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Gentamicin NICE Guidance on Gentamicin NHS PRODIGY Guidance FDA on Gentamicin CDC on Gentamicin
Books
Books on Gentamicin
News
Gentamicin in the news Be alerted to news on Gentamicin News trends on Gentamicin
Commentary
Blogs on Gentamicin
Definitions
Definitions of Gentamicin
Patient Resources / Community
Patient resources on Gentamicin Discussion groups on Gentamicin Patient Handouts on Gentamicin Directions to Hospitals Treating Gentamicin Risk calculators and risk factors for Gentamicin
Healthcare Provider Resources
Symptoms of Gentamicin Causes & Risk Factors for Gentamicin Diagnostic studies for Gentamicin Treatment of Gentamicin
Continuing Medical Education (CME)
CME Programs on Gentamicin
International
Gentamicin en Espanol Gentamicin en Francais
Business
Gentamicin in the Marketplace Patents on Gentamicin
Experimental / Informatics
List of terms related to Gentamicin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Gentamicin is an aminoglycoside antibiotic, and can treat many types of bacterial infections, particularly Gram-negative infection. However, gentamicin is not used for Neisseria gonorrhoeae, Neisseria meningitidis or Legionella pneumophila infections.

It is synthesized by Micromonospora, a genus of Gram-positive bacteria widely present in the environment (water and soil). Gentamicin is a bactericidal antibiotic that works by binding the 30S subunit of the bacterial ribosome, interrupting protein synthesis.

Like all aminoglycosides, when gentamicin is given orally, it is not systemically active. This is because it is not absorbed to any appreciable extent from the small intestine. It appears to be completely eliminated unchanged in the urine. Urine must be collected for many days to recover all of a given dose because the drug binds avidly to certain tissues. It is administered intravenously, intramuscularly or topically to treat infections.

E. coli has shown some resistance to gentamicin, despite being Gram-negative.

Gentamicin is one of the few heat-stable antibiotics that remain active even after autoclaving, which makes it particularly useful in the preparation of certain microbiological growth media.

Treatment of susceptible bacterial infections, normally gram-negative organisms including Pseudomonas, Proteus, Serratia, AND Gram-positive Staphylococcus; http://www.merck.com/mmpe/lexicomp/gentamicin.html

Side effects

All aminoglycosides are toxic to the sensory cells of the ear, but they vary greatly in their relative effects on hearing versus balance. Gentamicin is a vestibulotoxin, and can usually cause permanent loss of equilibrioception, caused by damage to the vestibular apparatus of the inner ear if taken at high doses or for prolonged periods of time. Gentamicin has on occasion impaired or even wholly destroyed hearing. In most instances, the affected individual has undergone treatment for 2 weeks or more. A small number of affected individuals have a normally harmless mutation in their mitochondrial RNA, that allows the gentamicin to affect their cells. The cells of the ear are particularly sensitive to this. Gentamicin is sometimes used intentionally for this purpose in severe Ménière’s disease, to disable the vestibular apparatus.

Gentamicin can also be highly nephrotoxic, particularly if multiple doses accumulate over a course of treatment. For this reason gentamicin is usually dosed by body weight. Various formulae exist for calculating gentamicin dosage. Also trough and peak serum levels of gentamicin are monitored during treatment, generally before and after the third dose is infused.

Gentamicin, like other aminoglycosides, causes nephrotoxicity by inhibiting protein synthesis in renal cells. This mechanism specifically causes necrosis of cells in the proximal tubule, resulting in acute tubular necrosis which can lead to acute renal failure.

Gentamicin producers

Gentamicin is produced by a fermentation procedure. The majority of the world's gentamicin production takes place in China and South Korea; the last European producer is Lek, part of Sandoz group [citation needed].

References

Complete Gentamicin Information at Drugs.com

bs:Gentamicin cs:Gentamicin de:Gentamicin hr:Gentamicin hu:Gentamicin nl:Gentamicine sr:Гентамицин sh:Gentamicin th:เจนตามัยซิน